Swaziland
Tuberculosis profile
| High HIV burden |
Population  2013 1.2 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.1 (0.74–1.4) 91 (59–116)
Mortality (HIV+TB only) 5 (4–6.1) 400 (320–488)
Prevalence  (includes HIV+TB) 12 (6.8–18) 945 (545–1 454)
Incidence  (includes HIV+TB) 17 (15–19) 1 382 (1 220–1 541)
Incidence (HIV+TB only) 13 (11–14) 1 038 (918–1 158)
Case detection, all forms (%) 38 (34–44)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 7.7 (4.8–11) 34 (28–39)
MDR-TB cases among notified pulmonary
TB cases
390 (240–530) 250 (210–290)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 2 761   289
Pulmonary, clinically diagnosed 2 257   0
Extrapulmonary 921   413
       
Total new and relapse 6 641    
Previously treated, excluding relapses 437    
Total cases notified 7 078    
Among 6 691 new and relapse cases:
671 (10%) cases aged under 15 years; male:female ratio: 1.2
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 435 (16%) 355 (31%) 802
Laboratory-confirmed RR-/MDR-TB cases     491
Patients started on MDR-TB treatment     199
TB/HIV 2013 Number (%)
TB patients with known HIV status 6 416 (91)
HIV-positive TB patients 4 747 (74)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 4 687 (99)
HIV-positive TB patients on antiretroviral therapy (ART) 3 806 (80)
HIV-positive people screened for TB 100 138  
HIV-positive people provided with IPT 429  
Treatment success rate (%)
New and relapse cases registered in 2012 72
Previously treated cases, excluding relapse, registered in 2012 65
HIV-positive TB cases, all types, registered in 2012 70
RR-/MDR-TB cases started on second-line treatment in 2011 58
XDR-TB cases started on second-line treatment in 2011 0
Laboratories 2013  
Smear (per 100 000 population) 1.4
Culture (per 5 million population) 4.0
Drug susceptibility testing (per 5 million population) 4.0
Sites performing Xpert MTB/RIF 18
Is second-line drug susceptibility testing available? No
Financing TB control 2014  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-08-02 Data: www.who.int/tb/data